Summit Therapeutics (SMMT) Operating Income (2017 - 2024)

Summit Therapeutics (SMMT) has 8 years of Operating Income data on file, last reported at -$65.6 million in Q4 2024.

• Quarterly Operating Income fell 81.2% year-over-year to -$65.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$226.0 million (up 62.93% YoY) and the FY2024 annual result came in at -$226.0 million, up 62.93% from the prior year.
• Operating Income retreated to -$65.6 million in Q4 2024, from -$58.4 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$9.3 million in Q1 2020 to a low of -$537.2 million in Q1 2023.
• A 5-year average of -$52.4 million and a median of -$20.4 million in 2022 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2023 — Operating Income slumped 2324.2% — and 2024, when it jumped 92.11%.
• Tracing SMMT's Operating Income over 5 years: stood at -$11.6 million in 2020, then plunged by 125.4% to -$26.0 million in 2021, then advanced by 22.07% to -$20.3 million in 2022, then plunged by 78.38% to -$36.2 million in 2023, then tumbled by 81.2% to -$65.6 million in 2024.
• The last three Operating Income figures came in at -$65.6 million (Q4 2024), -$58.4 million (Q3 2024), and -$59.6 million (Q2 2024), per Business Quant data.